Healthcare / Diagnostics & ResearchSES
$0.05
+0.00 (+1.92%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $-2.0M · quality 36.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
28/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$92M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-259.5%
↓Gross Margin
36.8%
↓Debt/Equity
1.58
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+28.3%
FCF CAGR
—
FCF margin
-6.8%
FCF / Net income
0.09x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.3M · net income $-4.0M · FCF $-360000.0
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.3M | $5.3M | $784000.00 | $277000.00 | $2.5M |
| Net Income | $-4.0M | $-4.0M | $-3.4M | $-2.5M | $-9.4M |
| EBITDA | $-3.7M | $-3.7M | $-3.0M | $-1.2M | $-8.5M |
| EPS | -0.00 | -0.00 | -0.00 | -0.00 | -0.03 |
| Gross Margin | 36.8% | 36.8% | 23.9% | 52.7% | 46.7% |
| Operating Margin | -60.0% | -60.0% | -217.1% | -359.6% | -121.9% |
| Net Margin | -75.3% | -75.3% | -438.0% | -898.2% | -376.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.58 | 1.58 | 1.01 | -1.02 | -1.78 |
| Current Ratio | 1.17 | 1.17 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-360000.00 | $-360000.00 | $-2.3M | $-2.0M | $-3.2M |
| Returns | |||||
| ROE | -259.5% | -259.5% | -198.3% | 125.1% | 555.3% |
| Valuation | |||||
| P/B | 118.85 | 118.85 | 30.59 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 570.8% | 570.8% | 183.0% | -88.9% | — |
| EPS Growth | 34.3% | 34.3% | 16.7% | 87.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+152.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.00
Residual
+152.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.